Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026)

Akari Therapeutics (AKTX) posted Tax Provisions of -$859000.0 for Q1 2026, down 1110.59% sequentially from $85000.0 in Q4 2025.

Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026) Analysis & Trends

Akari Therapeutics (AKTX) has 2 years of Tax Provisions data on file, last reported at -$859000.0 in Q1 2026.

Quarterly Tax Provisions changed N/A year-over-year to -$859000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (changed N/A YoY) and the FY2025 annual result came in at -$1.0 million, changed N/A from the prior year.
Tax Provisions slipped to -$859000.0 in Q1 2026 per AKTX's latest filing, from $85000.0 in the prior quarter.
The five-year high for Tax Provisions was $85000.0 in Q4 2025, with the low at -$1.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Genmab A	276,399.99 Bn	276,398.47 Bn	831.00 Mn	-
2	Akari Therapeutics	1,217.26 Bn	1,217.26 Bn	-	-859,000.00
3	BeOne Medicines	419.38 Bn	414.59 Bn	1.35 Bn	31.86 Mn
4	Vertex Pharmaceuticals	126.54 Bn	119.30 Bn	2.59 Bn	221.50 Mn
5	Pharming	110.17 Bn	110.12 Bn	65.80 Mn	-459,000.00
6	Regeneron Pharmaceuticals	64.97 Bn	56.22 Bn	3.31 Bn	104.00 Mn
7	Argenx Se	56.44 Bn	56.44 Bn	1.18 Bn	60.00 Mn
8	Alnylam Pharmaceuticals	40.09 Bn	37.08 Bn	959.66 Mn	15.66 Mn
9	Revolution Medicines	37.15 Bn	37.15 Bn	-	-
10	Moderna	28.64 Bn	23.43 Bn	-566.00 Mn	9.00 Mn

Download Data